CA2757240A1 - Formulation for inducing broadly reactive neutralizing anti-hiv antibodies - Google Patents
Formulation for inducing broadly reactive neutralizing anti-hiv antibodies Download PDFInfo
- Publication number
- CA2757240A1 CA2757240A1 CA2757240A CA2757240A CA2757240A1 CA 2757240 A1 CA2757240 A1 CA 2757240A1 CA 2757240 A CA2757240 A CA 2757240A CA 2757240 A CA2757240 A CA 2757240A CA 2757240 A1 CA2757240 A1 CA 2757240A1
- Authority
- CA
- Canada
- Prior art keywords
- ligand
- mper
- trl
- tnd
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000001939 inductive effect Effects 0.000 title claims abstract description 11
- 230000003472 neutralizing effect Effects 0.000 title abstract description 48
- 239000000203 mixture Substances 0.000 title abstract description 17
- 238000009472 formulation Methods 0.000 title abstract description 15
- 230000036436 anti-hiv Effects 0.000 title description 2
- 239000002502 liposome Substances 0.000 claims abstract description 67
- 102000002689 Toll-like receptor Human genes 0.000 claims abstract description 33
- 108020000411 Toll-like receptor Proteins 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 28
- 239000012528 membrane Substances 0.000 claims abstract description 14
- 230000006698 induction Effects 0.000 claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 64
- 239000003446 ligand Substances 0.000 claims description 32
- 230000002163 immunogen Effects 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 239000000562 conjugate Substances 0.000 claims 5
- 102100037473 Glutathione S-transferase A1 Human genes 0.000 claims 1
- 101001026125 Homo sapiens Glutathione S-transferase A1 Proteins 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000000863 peptide conjugate Substances 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 33
- 101800001690 Transmembrane protein gp41 Proteins 0.000 abstract description 15
- 239000000556 agonist Substances 0.000 abstract description 8
- 230000035772 mutation Effects 0.000 description 51
- 230000027455 binding Effects 0.000 description 48
- 238000006386 neutralization reaction Methods 0.000 description 47
- 230000035945 sensitivity Effects 0.000 description 40
- 241000700605 Viruses Species 0.000 description 32
- 102000004196 processed proteins & peptides Human genes 0.000 description 25
- 238000003556 assay Methods 0.000 description 23
- 210000003719 b-lymphocyte Anatomy 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 150000002632 lipids Chemical class 0.000 description 15
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 15
- 238000013461 design Methods 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- 230000005875 antibody response Effects 0.000 description 12
- 241000725303 Human immunodeficiency virus Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241001112090 Pseudovirus Species 0.000 description 8
- 210000000649 b-lymphocyte subset Anatomy 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 230000009977 dual effect Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 208000031886 HIV Infections Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 108091008875 B cell receptors Proteins 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- OIWCYIUQAVBPGV-DAQGAKHBSA-N {1-O-hexadecanoyl-2-O-[(Z)-octadec-9-enoyl]-sn-glycero-3-phospho}serine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC OIWCYIUQAVBPGV-DAQGAKHBSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 102100034353 Integrase Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- -1 POPE Chemical compound 0.000 description 2
- 101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 108010078428 env Gene Products Proteins 0.000 description 2
- 101150113423 hisD gene Proteins 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- WTJKGGKOPKCXLL-VYOBOKEXSA-N 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC WTJKGGKOPKCXLL-VYOBOKEXSA-N 0.000 description 1
- 229940124718 AIDS vaccine Drugs 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 229940033332 HIV-1 vaccine Drugs 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229940124613 TLR 7/8 agonist Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 108010085336 phosphoribosyl-AMP cyclohydrolase Proteins 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000012557 regeneration buffer Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- FHQVHHIBKUMWTI-OTMQOFQLSA-N {1-hexadecanoyl-2-[(Z)-octadec-9-enoyl]-sn-glycero-3-phospho}ethanolamine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC FHQVHHIBKUMWTI-OTMQOFQLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16662509P | 2009-04-03 | 2009-04-03 | |
| US61/166,625 | 2009-04-03 | ||
| PCT/US2010/001017 WO2010114628A2 (en) | 2009-04-03 | 2010-04-05 | Formulation for inducing broadly reactive neutralizing anti-hiv antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2757240A1 true CA2757240A1 (en) | 2010-10-07 |
Family
ID=42828908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2757240A Abandoned CA2757240A1 (en) | 2009-04-03 | 2010-04-05 | Formulation for inducing broadly reactive neutralizing anti-hiv antibodies |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9402917B2 (enExample) |
| EP (1) | EP2413951A4 (enExample) |
| JP (1) | JP2013505201A (enExample) |
| AU (1) | AU2010232915A1 (enExample) |
| CA (1) | CA2757240A1 (enExample) |
| WO (1) | WO2010114628A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1868651A4 (en) | 2005-04-12 | 2010-10-06 | Univ Duke | METHOD FOR INDUCTION OF NEUTRALIZING ANTIBODIES TO THE HIV VIRUS |
| EP2139516A4 (en) * | 2007-04-13 | 2011-06-29 | Univ Duke | METHOD FOR INDUCING NEUTRALIZING ANTIBODY AGAINST HIV |
| US20120070488A1 (en) * | 2007-09-28 | 2012-03-22 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
| US20140322262A1 (en) * | 2007-09-28 | 2014-10-30 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
| AU2010232915A1 (en) | 2009-04-03 | 2011-10-20 | Duke University | Formulation for inducing broadly reactive neutralizing anti-HIV antibodies |
| JP2013520498A (ja) * | 2010-02-25 | 2013-06-06 | デューク ユニバーシティー | 防御的抗ｈｉｖ−１抗体の産生を誘導する方法 |
| EP2668201A2 (en) * | 2011-01-28 | 2013-12-04 | Sanofi Pasteur SA | Immunological compositions comprising hiv gp41 polypeptide derivatives |
| WO2014020205A2 (es) * | 2012-07-31 | 2014-02-06 | Universidad De Granada | Inmunógenos anti-vih mejorados |
| EP3872097A1 (en) | 2012-10-19 | 2021-09-01 | The Council Of The Queensland Institute Of Medical Research | Improved human herpesvirus immunotherapy |
| WO2015048635A1 (en) | 2013-09-27 | 2015-04-02 | Duke University | Mper-liposome conjugates and uses thereof |
| WO2024097957A1 (en) * | 2022-11-03 | 2024-05-10 | Duke University | Novel antibodies for hiv and methods of making and using the same |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ263373A (en) | 1993-03-11 | 1997-05-26 | Univ Southern California | Monoclonal antibodies and use against immunoinfective cluster viruses |
| DE69433013T2 (de) | 1993-05-27 | 2004-06-03 | Entremed, Inc. | Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten |
| FI963638A7 (fi) | 1994-03-14 | 1996-11-13 | Univ Southern California | Menetelmiä HIV-1-injektion diagnosoimiseksi ja hoitamiseksi |
| US6156337A (en) | 1994-07-08 | 2000-12-05 | Opperbas Holding B.V. | Method for high loading of vesicles with biopolymeric substances |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP1250933A1 (en) * | 2001-04-17 | 2002-10-23 | Istituto Superiore di Sanità | Vaccines including as an adjuvant high dose type I IFN |
| EP2572714A1 (en) * | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
| EP1613643A4 (en) | 2003-03-27 | 2009-10-28 | Sudhir Paul | LUPUS ANTIBODIES FOR PASSIVE IMMUNOTHERAPY AGAINST HIV / AIDS |
| EP1868651A4 (en) | 2005-04-12 | 2010-10-06 | Univ Duke | METHOD FOR INDUCTION OF NEUTRALIZING ANTIBODIES TO THE HIV VIRUS |
| US20080057075A1 (en) | 2005-04-12 | 2008-03-06 | Haynes Barton F | Method of inducing neutralizing antibodies to human immunodeficiency virus |
| EP2139516A4 (en) | 2007-04-13 | 2011-06-29 | Univ Duke | METHOD FOR INDUCING NEUTRALIZING ANTIBODY AGAINST HIV |
| UY31101A1 (es) | 2007-05-24 | 2009-01-05 | Glaxosmithkline Biologicals Sa | Composición antigénica liofilizada |
| US20120070488A1 (en) | 2007-09-28 | 2012-03-22 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
| US20140322262A1 (en) | 2007-09-28 | 2014-10-30 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
| WO2009111304A2 (en) | 2008-02-29 | 2009-09-11 | President And Fellows Of Harvard College | A fusion-intermediate state of hiv-1 gp41 targeted by broadly neutralizing antibodies |
| SMT202000101T1 (it) | 2008-10-10 | 2020-03-13 | Childrens Medical Center | Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente |
| WO2010045613A1 (en) | 2008-10-16 | 2010-04-22 | New York Blood Center | Immunoenhancer-linked oligomeric hiv vaccines |
| AU2010232915A1 (en) | 2009-04-03 | 2011-10-20 | Duke University | Formulation for inducing broadly reactive neutralizing anti-HIV antibodies |
| CA2757306A1 (en) * | 2009-04-03 | 2010-10-07 | Duke University | Formulation |
-
2010
- 2010-04-05 AU AU2010232915A patent/AU2010232915A1/en not_active Abandoned
- 2010-04-05 US US13/262,706 patent/US9402917B2/en active Active
- 2010-04-05 JP JP2012503432A patent/JP2013505201A/ja active Pending
- 2010-04-05 CA CA2757240A patent/CA2757240A1/en not_active Abandoned
- 2010-04-05 EP EP10759166.1A patent/EP2413951A4/en not_active Withdrawn
- 2010-04-05 WO PCT/US2010/001017 patent/WO2010114628A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013505201A (ja) | 2013-02-14 |
| WO2010114628A9 (en) | 2010-11-25 |
| US20120128758A1 (en) | 2012-05-24 |
| AU2010232915A1 (en) | 2011-10-20 |
| EP2413951A2 (en) | 2012-02-08 |
| US9402917B2 (en) | 2016-08-02 |
| EP2413951A4 (en) | 2015-05-20 |
| WO2010114628A3 (en) | 2011-03-10 |
| WO2010114628A2 (en) | 2010-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9402917B2 (en) | Methods for the induction of broadly anti-HIV-1 neutralizing antibody responses employing liposome-MPER peptide compositions | |
| US10588960B2 (en) | Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies | |
| Matyas et al. | Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes | |
| Dennison et al. | Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41 | |
| Bi et al. | An HIV-1 vaccine based on bacterium-like particles elicits Env-specific mucosal immune responses | |
| US20150147387A1 (en) | Method of inducing antibodies to human immunodeficiency virus involving the administration of mper peptide-liposome conjugates | |
| ES2366185T3 (es) | Vacunas de péptidos sintéticas para vih: el epítopo de cbd como un inmunógeno eficaz para provocar anticuerpos ampliamente neutralizantes contra el vih. | |
| US10076567B2 (en) | MPER-liposome conjugates and uses thereof | |
| US20080057075A1 (en) | Method of inducing neutralizing antibodies to human immunodeficiency virus | |
| Watson et al. | Role of lipid structure in the humoral immune response in mice to covalent lipid–peptides from the membrane proximal region of HIV-1 gp41 | |
| Yu et al. | The binding of HIV-1 gp41 membrane proximal domain to its mucosal receptor, galactosyl ceramide, is structure-dependent | |
| Koornneef et al. | CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits | |
| US20220040290A1 (en) | Compositions comprising supramolecular nanofiber hiv envelopes and methods for their use | |
| US20110159037A1 (en) | Methods of treating and protecting against human immunodeficiency virus | |
| Wegmann et al. | A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment | |
| US20250073328A1 (en) | Compositions and methods for treating or preventing hiv infection | |
| CN101588813A (zh) | 诱导人类免疫缺陷病毒的中和抗体的方法 | |
| Watson | Lipopeptide immunogens targeting the membrane proximal region of HIV-1 gp41 | |
| Melnychuk | Optimization of an HIV-1 clade C DNA vaccine | |
| Davis et al. | change in SHIV MNA Env, which renders sequestered | |
| HK1072264B (en) | Synthetic peptide vaccines for hiv: the cbd epitope as an effective immunogen to elicit broadly neutralizing antibodies against hiv | |
| AU2014202366A1 (en) | Method of Inducing Neutralizing Antibodies to Human Immunodeficiency Virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150401 |
|
| FZDE | Dead |
Effective date: 20170906 |